

# Association between neutrophil gelatinase-associated lipocalin and iron deficiency anemia in children on chronic dialysis

Mohammad Yazdani, Alireza Merrikhi<sup>1</sup>, Zahra Naderi Beni<sup>2</sup>, Azar Baradaran<sup>2</sup>, Neda Soleimani<sup>2</sup>, Hamided Musazade<sup>1</sup>

Department of Urology, Isfahan University of Medical Sciences, <sup>1</sup>Department of Pediatrics Nephrology, Isfahan University of Medical Sciences,

<sup>2</sup>Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran

**Background:** Iron deficiency anemia (IDA) in children with chronic kidney disease (CKD) is common and associated with higher risk of death. Neutrophil gelatinase-associated lipocalin (NGAL) is a small 25 kDa glycoprotein, a member of lipocalin superfamily that released at the response of cellular stress from different cells. In addition, NGAL was studied as an iron regulatory glycoprotein and regulator of iron related gene. The aim of the current study was to determine any association between serum NGAL and body iron status markers in children on chronic dialysis. **Materials and Methods:** This correlation study was carried out between May 2012 and May 2013 and evaluated all dialysis patients less than 19 years in pediatric dialysis centers in Isfahan that didn't have exclusion criteria. They were 40 children, including 23 persons on hemodialysis (HD) and 17 persons dialyzed by peritoneal dialysis (PD). Furthermore, we selected 40 children as healthy controls. We examined the relationship between plasma NGAL levels and indices of anemia such as ferritin, transferrin saturation (TSAT) and serum iron (SI) in dialysis children. **Results:** Serum NGAL level in children on chronic dialysis (group including both PD and HD patients) was significantly higher than healthy controls ( $P = 0.008$ ). Furthermore, in this group Serum NGAL level had inverse correlation with TSAT ( $P = 0.04$ ,  $r = -0.22$ ), SI ( $P = 0.04$ ,  $r = -0.2$ ), white blood cells ( $P = 0.045$ ,  $r = -0.26$ ) and serum ferritin ( $P = 0.006$ ,  $r = -0.3$ ). In addition, HD patients had higher serum NGAL level than PD patients ( $P = 0.048$ ). **Conclusion:** High serum NGAL level in low TSAT group demonstrated that NGAL probably has an important role in IDA in children on chronic dialysis; therefore, it can be a new marker for diagnosis of IDA in CKD.

**Key words:** Hemodialysis, iron deficiency anemia, neutrophil gelatinase-associated lipocalin, peritoneal dialysis

**How to cite this article:** Yazdani M, Merrikhi A, Beni ZN, Baradaran A, Soleimani N, Musazade H. Association between neutrophil gelatinase-associated lipocalin and iron deficiency anemia in children on chronic dialysis. *J Res Med Sci* 2014;19:624-8.

## INTRODUCTION

About 90 % of patients with end stage renal disease (ESRD) have anemia<sup>[1]</sup> and it is associated with higher risk of death.<sup>[2]</sup> It seems common cause of anemia in children with ESRD is erythropoietin (EPO) deficiency,<sup>[3]</sup> but in many situations it is hyporesponsive to EPO. Its causes are different such as iron deficiency anemia (IDA)<sup>[4]</sup> and inflammation.<sup>[5]</sup> Children on chronic dialysis often have IDA, because of multiple blood sampling, gastrointestinal bleeding, dietary restriction, and decreased intestinal absorption due to phosphate medication.<sup>[6]</sup> According to Kidney Disease Outcome Quality Initiative suggestion, transferrin saturation (TSAT) and ferritin are the first tools for evaluation of iron status in renal disease. TSAT <20, ferritin <200 are two cut-off points for IDA in patients on chronic dialysis.<sup>[7]</sup> There are some difficulties about these markers, first ferritin is an acute phase protein and is different in both sexes,<sup>[8]</sup> second TSAT also influences by malnutrition, chronic

disease and inflammation, but it is more reliable than ferritin for evaluation of body iron status in patients on chronic dialysis.<sup>[9]</sup>

Neutrophil gelatinase-associated lipocalin (NGAL) is a small 25 kDa glycoprotein, a member of lipocalin superfamily that released at the response of cellular stress such as inflammation and ischemia from different cells such as renal tubules, liver hepatocytes, endothelial, and smooth muscle cells.<sup>[10-16]</sup>

Now-a-days, serum NGAL uses as an acute kidney injury marker, but basically it is a bacteriostatic substance that released from secondary granules of neutrophils.<sup>[17,18]</sup> In addition, NGAL was studied as an iron regulatory glycoprotein and regulator of iron related gene.<sup>[19-23]</sup> Later investigations show NGAL causes anemia due to oxidative stresses. In experimental models, medullary and systemic NGAL causes erythropoiesis inhibition through induction of apoptosis and inhibition erythroid precursor

**Address for correspondence:** Dr. Zahra Naderi Beni, No. 21, Khomeini Shahr, Shariati Street, Mohvash Block, Pathological Lab, Alzahra Hospital, Sofeh Street, Isfahan, Iran. E-mail: znaderi89@yahoo.com

**Received:** 26-06-2013; **Revised:** 02-12-2013; **Accepted:** 20-05-2014

differentiation.<sup>[24-28]</sup> NGAL also at the response of renal tubular cell injury, redirect systemic iron to proximal tubule cells of kidney.<sup>[21,29]</sup>

Another study was done former on adults on chronic hemodialysis (HD) that show relationship between IDA and serum NGAL.<sup>[30]</sup> However, on the basis of our knowledge, no study has yet performed about association between serum NGAL level and IDA in children on chronic dialysis.

The aim of current pilot study was to evaluate the association between serum NGAL and body iron status in children on chronic dialysis.

## MATERIALS AND METHODS

### Study design and participants

This correlation study was performed between May 2012 and May 2013. We selected for current study children who received treatment for ESRD (either HD or peritoneal dialysis [PD]) for a minimum of 6 months and didn't have exclusion criteria at all Isfahan dialysis centers. They were 40 patients, including 23 persons on HD and 17 person dialyzed by PD. Exclusion criteria were the presence or a recent history of bleeding, malignancy, liver, thyroid or infectious disease, recent increase in leukocyte count or treatment with immunosuppressor drugs.

HD group were on regular treatment for dialysis, 3 times a week about 4 h/each session on standard bicarbonate dialysis. HD and PD patients matched for age and sex and duration of dialysis. All dialysis children were on recombinant EPO treatment for at least 6 month, none of them received iron or RBC in past 2 mounts. They were normotensive without edema. Causes of ESRD in these children were hypoplasia/dysplasia ( $n = 22$ ), reflux nephropathy ( $n = 8$ ), drug reaction ( $n = 2$ ), metabolic disease ( $n = 3$ ), and unknown ( $n = 5$ ).

Control group was selected of healthy children that referred to clinic for assessment of body iron status. This group was matched for age, sex with dialysis children. They were on regular diet without consumption supplementary iron drugs.

### Procedures and variable assessment

Sampling was carried out at hospital dialysis unit for HD patients and at routine laboratory assessment for PD patients. Samples transferred on ice to laboratory unit and quickly freeze on  $-20^{\circ}\text{C}$ . Fasting serum samples were obtained in the early morning for biochemical studies. These biochemical variables were Cr, urea, hemoglobin, hematocrit, leukocyte count, serum iron (SI), TSAT, ferritin,

transferrin iron binding capacity (TIBC), albumin, alkaline phosphates, para thyroid hormone, high-sensitivity C-reactive protein (hsCRP), and NGAL. All biochemical blood samples were collected before mid-week dialysis session in HD group.

Markers that measured for assessment of body iron status were SI, TSAT, ferritin, TIBC.

SI, ferritin measured by radioimmunoassay. TIBC measured through spectrophotometry. TSAT calculated by this formula:  $\frac{\text{SI}}{\text{TIBC}} \times 100$ . Serum CRP was obtained to demonstrate the presence of inflammation and measured by immunoturbidometry. Plasma NGAL level measured by researched enzyme-linked immunosorbent assay (LOT. NO. KIT EKO 853, BOSTER biological Technology Co., Ltd.; Wuhan, China). Minimum detection limit was 10 ng/mL and coefficient of variation was  $<5\%$ .

Other measurements were performed by routine automated laboratory tests.

Iron deficiency was defined as TSAT  $<20\%$  and used for subdivision of patients to two groups to assessment correlation between serum NGAL level and iron status in children on chronic dialysis.

### Statistics analysis

Data presented as mean  $\pm$  standard deviation. Data analysis was performed by SPSS version 16 (SPSS Inc., Chicago, IL, USA). Normality of variables was assessed by Kolmogorov-Smirnov test.

Differences between groups were determined by unpaired *t*-test and level of significance was 0.05. Pearson correlation coefficient test was used to show relationship between serum NGAL and different data. Chi-square test used for nonnumerical variables.

## RESULTS

Table 1 illustrates the main characteristics of this study In group, including both HD and PD patients the mean age was  $9 \pm 2$ . Mean serum NGAL level was  $327.3 \pm 29.8$  ng/mL, which was significantly higher than healthy controls ( $P = 0.008$ ).

Hematologic markers (Hb and Hct) and iron status markers (TSAT, SI) in this group was significantly higher than healthy controls ( $P < 0.001$ ). Inflammatory markers (such as hsCRP and ferritin), urea and creatinine as expected were higher than healthy controls ( $P < 0.05$ ). Serum NGAL level in this group had inverse correlation with TSAT ( $P = 0.04$ ,

$r = -0.22$ ), SI ( $P = 0.04$ ,  $r = -0.2$ ), white blood cells ( $P = 0.045$ ,  $r = -0.26$ ), and serum ferritin ( $P = 0.006$ ,  $r = -0.3$ ). Serum NGAL level in HD group also had inverse correlation with TSAT ( $P = 0.038$ ,  $r = -0.18$ ), SI ( $P = 0.042$ ,  $r = -0.21$ ).

Correlation between serum NGAL level in PD group and iron status markers such as SI, TSAT, and ferritin was reverse, but not significant ( $P = 0.063$ ,  $r = -0.34$ ).

### Iron balance in children on chronic dialysis

Children on chronic dialysis was subdivided to two groups on the basis on absence or presence of IDA according to TSAT <20 (low TSAT group) or TSAT >20 (high TSAT group), so 17 patients (45%) belonged to low TSAT group and 23 patients (55%) belonged to high TSAT group, surprisingly between low TSAT group only 8 person (50%) simultaneously presented serum ferritin level under 200. Differences between low TSAT group and high TSAT group were summarized in Table 2. Serum NGAL in low TSAT group was significantly higher than high TSAT group ( $P = 0.04$ ). SI ( $P < 0.001$ ), TIBC ( $P = 0.04$ ), TSAT ( $P < 0.001$ ) were significantly higher in high TSAT group. Differences in Hb, Hct, and ferritin between these two groups were not significant. Creatinine and urea in high TSAT group was higher than low TSAT group, but not significant ( $P > 0.05$ ).

### Comparison between hemodialysis and peritoneal dialysis patients

Table 3 summarized results of comparison between HD and PD patients.

A total of 17 patients (41%) belonged to PD group and 23 patients (49%) belonged to HD group. HD patients presented significantly higher TSAT ( $P = 0.048$ ), SI ( $P = 0.047$ ), NGAL (0.04), urea ( $P = 0.010$ ), and ALP ( $P = 0.001$ ) than PD patients. Differences between hemoglobin and hematocrit between PD and HD patients were not significant ( $P > 0.05$ ). Urea was significantly higher in PD than HD patients ( $P = 0.010$ ). Creatinine was higher in PD patients, but not significant ( $P = 0.34$ ).

## DISCUSSION

There are some points to discussion in our study.

First, serum NGAL level in children on chronic dialysis was higher than healthy controls. We expected this consequence because according to previous studies NGAL was known as an acute phase protein that released by injured tissue such as renal cells.<sup>[31]</sup> In renal disease serum NGAL known as a primary indicator of organ damage<sup>[32]</sup> and in patients with chronic kidney disease (CKD) increased serum and urine level of NGAL is correlated with residue of renal function.

**Table 1: Main clinical and laboratory characteristic of the patients**

Parameter	Patients (n = 40)	Controls (n = 40)	P value
Gender (male/female)	19/21	11/9	0.61
Age (years)	9±2	9±5	0.898
Creatinine (mg/dL)	6.21±0.3	0.75±0.2	<0.001
Urea (mg/dL)	53.9±21	8.5±2	<0.001
Hemoglobin (g/dL)	8.8±2.04	12.5±1.11	<0.001
Hematocrit (%)	27.05±6.26	36.6±3.2	<0.001
ALP (IU/L)	455.31±289	-	-
PTH (pg/dL)	141.4±156	-	-
WBC ( $n \times 10^6$ )	7.269±3.55	6.31±2.1	0.06
Albumin (g/dL)	5.44±12.43	5.34±10.2	0.44
hsCRP (mg/L)	6.2±17	0.11±0.03	0.04
Serum iron (mcg/mL)	75.05±28	105±12.2	<0.001
TIBC (mg/dL)	225±83	402.1±53.2	0.01
TSAT (%)	26.07±12.6	34.8±6.69	0.006
NGAL (ng/mL)	327.38±29.8	142.7±78.7	0.008
Ferritin (ng/mL)	166.5±164.5	118.7±44.02	0.208

hsCRP = High-sensitivity C-reactive protein; ALP = Alkaline phosphatase; TSAT = Transferrin saturation; TIBC = Transferrin iron binding capacity; PTH = Para thyroid hormone; NGAL = Neutrophil gelatinase-associated lipocalin; WBC = White blood cell

**Table 2: Comparison between low TSAT group and high TSAT group in main clinical**

Parameters	TSAT <20% (n = 16)	TSAT >20% (n = 24)	P value
Gender (male/female)	7/9	14/10	0.56
Age (years)	9±5.5	9.6±0.4	0.73
Creatinin (mg/dL)	6.49±2.6	0.04±0.44	0.564
Urea (mg/dL)	55.8±15	52.62±23	0.658
Hb (g/dL)	9.25±1.9	8.6±2.1	0.35
Hematocrit (%)	28.57±5.4	26.03±6.6	0.21
ALP (IU/L)	424.15±244	522.8±387	0.505
PTH	113.7±69	159.9±194	0.36
WBC ( $n \times 10^6$ )	7.51±3.69	7.10±3.53	0.72
Albumin (g/dL)	3.48±0.78	6.74±16	0.424
hsCRP (mg/dL)	10.36±23	3.43±10.2	0.214
Serum iron (mcg/mL)	54±15	88.7±27	<0.0 01
TIBC (mg/dl)	249.6±67	209.2±89	0.04
TSAT (%)	13.8±4.32	34.25±9.19	<0.001
Serum ferritin (ng/mL)	205.06±186	140.9±146	0.232
NGAL	371.3±314	261.4±267	0.04

hsCRP = High-sensitivity C-reactive protein; ALP = Alkaline phosphatase; TSAT = Transferrin saturation; TIBC = Transferrin iron binding capacity; PTH = Para thyroid hormone; NGAL = Neutrophil gelatinase-associated lipocalin; WBC = White blood cell

Second, there was a significant reverse correlation between serum NGAL and SI, TSAT, and ferritin in our study, this consequence can illustrated on the basis of previous investigations such as in one study, NGAL level was measured in blood, liver, and spleen after experimental induction of different types of anemia such as blood loss (phlebotomy, anemia induced by bleeding), IDA (sideropenic anemia) and hemolytic anemia (after phenyl

**Table 3: Comparison between HD and PD patients in main parameters**

Parameters	PD (n = 17)	HD (n = 23)	P value
Gender (male/female)	7/10	12/11	0.246
Age (years)	8±1	10±1	0.268
Hemoglobin (g/dL)	9.26±0.96	8.7±4.5	0.403
WBC (n×10 <sup>6</sup> )	8364±890	4622±700	0.09
Serum ferritin (ng/mL)	199±43	145±32	0.316
hsCRP (mg/dL)	8±6	2.5±1.9	0.349
Serum iron (mcg/Dl)	66±8	83±4.4	0.047
TIBC (mg/dL)	271±8	185±14	0.001
Creatinine (mg/dL)	6.6±0.7	5.6±0.35	0.345
Urea (mg/dL)	63±6	45±0.6	0.010
ALP (IU/L)	414±53	463±69	0.001
Albumin (g/dL)	3.3±0.18	7.15±3.56	0.361
Hematocrit (%)	28.7±1.36	26±1.38	0.191
PTH (pg/m)	119.7±16	158±43	0.456
NGAL (mg/mL)	234.752±639	368.386±612	0.04
TSAT (%)	19.2±5.24	35.01±8.21	0.048

PD = Peritoneal dialysis; HD = Hemodialysis; hsCRP = High-sensitivity C-reactive protein; ALP = Alkaline phosphatase; TSAT = Transferrin saturation; TIBC = Transferrin iron binding capacity; PTH = Para thyroid hormone; NGAL = Neutrophil gelatinase-associated lipocalin; WBC = White blood cell

hydrazine injection). In three upper situations, NGAL significantly increased in multiple organs such as liver and in two former conditions SI was decreased.<sup>[31]</sup> In one animal model, NGAL was able to separate iron from transferrin and redirect it from liver and spleen to renal proximal tubules to induce proliferation of these cells and inhibit their apoptosis.<sup>[30]</sup> In this study, serum NGAL level in low TSAT group was significantly higher than high TSAT group. According to findings of our study and previous investigations, we found out that NGAL except its role in prevention of erythropoiesis has an important role in production of IDA in CKD, it seem that mechanism of this effect is complicated, but its function in separating iron from transferrin and redirects it to proximal renal tubules can plays an important role.

In addition, comparison between low TSAT group and serum ferritin level under 200 revealed that ferritin was not an ideal marker for diagnosis IDA in CKD. Therefore, serum NGAL can be a new marker for diagnosis of IDA in CKD that more investigations with more participants need in future.

Third, it is well-known that HD patients have severe anemia than PD patients even with EPO treatment but SI in HD patients was higher than PD patients as a result of recurrent blood transfusion.<sup>[33]</sup> In addition to PD patients have better renal residual function than HD patients,<sup>[33]</sup> therefore on the basis of our findings in this study, we can explain these findings. NGAL level was higher in HD patients because of severe anemia and lower renal residual function in these patients.

## Limitations

There were some limitations in the current study. First, participants were not as high as can extend these findings to all children on chronic dialysis. Second, we didn't correct IDA and then measure NGAL level to identify cause-and-effect relationship between serum NGAL and IDA.

## ACKNOWLEDGMENT

This study with research project number 390,544 was supported by Department of Pathology of Medical Isfahan University. We also appreciate from all dialysis children that we learned by cost of their pain.

## AUTHOR'S CONTRIBUTIONS

MY carried out the design and coordinates the study. ZN carried out the design and coordinates the study, and carried out all the experiments and prepared the manuscript. AB and AM provide assistance in the design of the study. NS and HM provided assistance for most experiments. All authors have read and approved the content of the manuscript.

## REFERENCES

1. Korbet SM. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. *Kidney Int Suppl* 1993;40:S111-9.
2. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. *J Am Soc Nephrol* 2006;17:1181-91.
3. Giordano C, De Santo NG, Carella C, Mioli V, Bazzato G, Amato G, et al. TSH response to TRH in hemodialysis and CAPD patients. *Int J Artif Organs* 1984;7:7-10.
4. Alvestrand A, Mujagic M, Wajngot A, Efendic S. Glucose intolerance in uremic patients: The relative contributions of impaired beta-cell function and insulin resistance. *Clin Nephrol* 1989;31:175-83.
5. Fishbane S, Kalantar-Zadeh K, Nissenson AR. Serum ferritin in chronic kidney disease: Reconsidering the upper limit for iron treatment. *Semin Dial* 2004;17:336-41.
6. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. *Am J Kidney Dis* 2003;42:761-73.
7. KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. *Am J Kidney Dis* 2006;47:S11-145.
8. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: The role of inflammation. *Clin J Am Soc Nephrol* 2008;3:1691-701.
9. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. *Clin J Am Soc Nephrol* 2006;1 Suppl 1:S4-8.
10. Xu S, Venge P. Lipocalins as biochemical markers of disease. *Biochim Biophys Acta* 2000;1482:298-307.
11. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, et al. Dual action of neutrophil gelatinase-associated lipocalin. *J Am Soc Nephrol* 2007;18:407-13.
12. Cowland JB, Sørensen OE, Sehested M, Borregaard N. Neutrophil

- gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. *J Immunol* 2003;171:6630-9.
13. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, *et al.* Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. *Arterioscler Thromb Vasc Biol* 2006;26:136-42.
  14. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. *Genomics* 1997;45:17-23.
  15. Cowland JB, Muta T, Borregaard N. IL-1beta-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. *J Immunol* 2006;176:5559-66.
  16. Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, Eriksson P, *et al.* Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. *Am J Pathol* 2006;169:2245-53.
  17. Xu SY, Carlson M, Engström A, Garcia R, Peterson CG, Venge P. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. *Scand J Clin Lab Invest* 1994;54:365-76.
  18. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. *J Biol Chem* 1993;268:10425-32.
  19. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, *et al.* Lipocalin 2 mediates an innate immune response to bacterial infection by sequestering iron. *Nature* 2004;432:917-21.
  20. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. *Kidney Int* 2007;71:967-70.
  21. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, *et al.* Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. *J Clin Invest* 2005;115:610-21.
  22. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, *et al.* An iron delivery pathway mediated by a lipocalin. *Mol Cell* 2002;10:1045-56.
  23. Barasch J, Mori K. Cell biology: Iron thievery. *Nature* 2004;432:811-3.
  24. Haase M, Bellomo R, Haase-Fielitz A. Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury. *J Am Coll Cardiol* 2010;55:2024-33.
  25. Devireddy LR, Teodoro JG, Richard FA, Green MR. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. *Science* 2001;293:829-34.
  26. Bolignano D, Coppolino G, Donato V, Lacquaniti A, Bono C, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL): A new piece of the anemia puzzle? *Med Sci Monit* 2010;16:RA131-5.
  27. Miharada K, Hiroyama T, Sudo K, Danjo I, Nagasawa T, Nakamura Y. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. *J Cell Physiol* 2008;215:526-37.
  28. Miharada K, Hiroyama T, Sudo K, Nagasawa T, Nakamura Y. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion. *FASEB J* 2005;19:1881-3.
  29. Sephton RG, Hodgson GS, De Abrew S, Harris AW. Ga-67 and Fe-59 distributions in mice. *J Nucl Med* 1978;19:930-5.
  30. Jiang W, Constante M, Santos MM. Anemia upregulates lipocalin 2 in the liver and serum. *Blood Cells Mol Dis* 2008;41:169-74.
  31. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M. Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. *Kidney Blood Press Res* 2008;31:255-8.
  32. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, *et al.* Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. *Am J Kidney Dis* 2008;52:595-605.
  33. House AA, Pham B, Pagé DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. *Nephrol Dial Transplant* 1998;13:1763-9.

**Source of Support:** Nil, **Conflict of Interest:** None declared.